Provided by Tiger Fintech (Singapore) Pte. Ltd.

Oric Pharmaceuticals Inc.

5.10
-0.0900-1.73%
Post-market: 5.100.00000.00%17:05 EDT
Volume:362.90K
Turnover:1.85M
Market Cap:362.24M
PE:-2.78
High:5.17
Open:5.08
Low:4.91
Close:5.19
Loading ...

Oric Pharmaceuticals Inc : Jefferies Raises Target Price to $22 From $18

THOMSON REUTERS
·
19 Feb

Oppenheimer Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
19 Feb

Oric Pharmaceuticals announces upcoming milestones

TIPRANKS
·
19 Feb

Oric Pharmaceuticals Inc - Cash and Investments of $256 Million to Fund Operations Into Late 2026

THOMSON REUTERS
·
19 Feb

BRIEF-ORIC Pharmaceuticals Q4 Net Income USD -36.307 Million

Reuters
·
19 Feb

Oric Pharmaceuticals Q4 Operating Expenses USD 39.57 Million

THOMSON REUTERS
·
19 Feb

Oric Pharmaceuticals Q4 Basic EPS USD -0.51 VS. Ibes Estimate USD -0.51

THOMSON REUTERS
·
19 Feb

ORIC® Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Updates

GlobeNewswire
·
19 Feb

Oric Pharmaceuticals (ORIC) Receives a Buy from Stifel Nicolaus

TIPRANKS
·
18 Feb

Buy Rating on Oric Pharmaceuticals: Capitalizing on Prostate Cancer Treatment Advances

TIPRANKS
·
14 Feb

Wedbush Remains a Buy on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
14 Feb

Oric recent weakness a buying opportunity, says JPMorgan

TIPRANKS
·
12 Feb

Oric Pharmaceuticals Price Target Maintained With a $21.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Feb

Analysts Offer Insights on Healthcare Companies: Oric Pharmaceuticals (ORIC), Inmune Bio (INMB) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
11 Feb

Oric Pharmaceuticals: Promising Trials and Strong Financials Justify Buy Rating

TIPRANKS
·
11 Feb

Oric Pharmaceuticals Is Maintained at Buy by Guggenheim

Dow Jones
·
10 Feb

Optimistic Buy Rating for Oric Pharmaceuticals Driven by Promising Data and Favorable Risk/Reward Profile

TIPRANKS
·
10 Feb

BRIEF-Oric Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
08 Feb

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
08 Feb

Wedbush Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)

TIPRANKS
·
07 Feb